OBJECTIVES : To provide budget impact analysis (BIA) of gadoterate meglumine for the MRI diagnosis in the Russian Federation.

METHODS : Budget impact analysis for gadoterate meglumine (GM), gadobutrol (GL), gadodiamide (GD), gadoteridol (GT), gadopentetic acid (GA) was conducted. Direct cost for these medicines with respect to existed dosage forms were considered. 3 year time horizon was used. Current patient distribution was obtained from marketing data. According to it, 42,64% of 576015 patients during the first year, 633617 patients during the second year and 696978 during the third year used GL; 5,54% used GT; 4,46% used GM, 28,58% used GD and 18,78% used GA. In the simulated patient distribution share of GL decreased from 40% on the first year to 30% on the third, share of GD from 24% to 12%; share of GA from 17% to 8%; while share of GM increased from 10% to 30% and share of GT from 9% to 20%. Exchange rate was 1 Euro = 81 RUR.

RESULTS : The result of BIA showed that the budget in the first year with current patient distribution will amount to €23,05 mln., and with the expected – €22,59 mln.; the budget for three years under current distribution will amount to €76,32 mln. (€71,81 mln. after discounting 3.0%), and at the expected – €69,73 mln. (€65,61 mln. after discounting 3.0%).

CONCLUSIONS : Based on the given distribution of patients for current and expected practice, it was found that the use of gadoterate meglumine as a contrast agent for MRI diagnostics will be accompanied by a cost savings of €473181 for the first year and €6,60 mln. for 3 years (€6,2 mln. after discounting 3.0%).